PubMed Health⌕ Search

Biomedical subjects

E Van Doorslaer

Publications and source records attributed to E Van Doorslaer.

At least 19 recordsLinked to original sources

Effects of cost sharing on physician utilization under favourable conditions for supplier-induced demand.

The effects of cost sharing on the demand for ambulatory care in experimental circumstances are well understood since the Rand Health Insurance Experiment (HIE). However, in a non-experimental real-world context, supplier-induced demand of doctors might erode some of the significant negative out-of-pocket price elasticity identified in the HIE. Belgium is an interesting test case for this hypothesis because it has relatively high rates of patient cost sharing in its public health insurance system and a very high density of physicians, all remunerated fee-for-service. We have exploited the price variation generated by a substantial increase in patient co-payment rates in 1994 to estimate out-of-pocket price elasticities for three groups of users, and for three types of services using a fixed-effects model in levels and in differences. We obtain significant out-of-pocket price elasticities for the general population in the range from -0.39 to -0.28 for GP home visits, -0.16 to -0.12 for GP office visits and -0.10 for specialist visits. The estimates were generally lower and less significant for the groups of elderly and disabled. The differences we find in price responsiveness appear to be fairly robust and consistent with the HIE predictions. These results suggest that--at least in the short run--non-experimental utilization effects of cost sharing are very similar to the experimental evidence, even in a situation of favourable conditions for supplier-induced demand.

Ambulatory Care↗

Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.

UNLABELLED: Acellular pertussis vaccines are less reactogenic than whole cell pertussis vaccines, but they are also more expensive. Based on simulation models, we compared the costs and effects of three alternative pertussis vaccination strategies in German children to "no prevention": (1) vaccination with whole-cell vaccine at 45% coverage (vaccine efficacy 90%), (2) vaccination with acellular vaccine at 45% coverage (vaccine efficacy 85%), and (3) vaccination with acellular vaccine at 90% coverage. In the two low coverage scenarios expected annual savings in direct medical costs through prevention of disease were larger for whole-cell than for acellular vaccination (252 vs 216 million DM, respectively). Direct costs for treating the more important adverse events induced by whole-cell vaccination (16.9 million DM annually) did not outweigh the higher direct costs of pertussis infections not prevented with the acellular vaccine and the higher price of the acellular vaccine. However, vaccination with acellular pertussis vaccine rapidly becomes as cost saving as vaccination with whole-cell vaccine as soon as vaccination coverage can be raised from 45% to 52.5% with acellular vaccine. Acellular vaccination is also the superior alternative when considering indirect cost savings resulting from reduction in work-loss due to adverse events. CONCLUSION: In our simulations, the most cost-effective pertussis prevention strategy was the use of an effective whole-cell vaccine with a high coverage rate. Introduction of the more expensive acellular pertussis vaccines becomes cost saving if at least a 7.5% increase in coverage is achieved. If also non-medical indirect costs to parents resulting from vaccine associated side-effects are accounted for, acellular vaccines may be more cost-effective also in countries with already high whole-cell vaccine coverage.

Child↗

Costs and benefits of routine varicella vaccination in German children.

This study assessed the costs and benefits of introducing routine varicella vaccination to healthy children in Germany. Three vaccination strategies were compared with that of no prevention: vaccination of all 15-month-old children: vaccination of susceptible 12-year-olds (adolescent); and a combination of strategies (children including catch-up). From a purely economic viewpoint, the adeolescent strategy was optimal: It was the only one that resulted in net direct cost savings. However, since this strategy may be less acceptable from a medical or organizational point of view and because total net savings were the highest, a second option was to begin immunization starting with the 15-month-old children and to use the catch-up strategy for 11 years (total benefit-to-cost ratio (BCR), 4.72:1; cost-effectiveness ratio (CER), DM 6915 per life-year saved) and from year 12 on to use the first strategy (BCR, 4.60:1; CER, DM 19,735 per life-year saved).

Adolescent↗

Hepatitis B prevention in Europe: a preliminary economic evaluation.

The World Health Organization (WHO) estimates that about 350 million people in the world are carriers of the hepatitis B virus (HBV), 60 million of whom may die from liver cancer and about 45 million from cirrhosis. In the WHO European Region, which has a total population of 839 million inhabitants, the average number of acute hepatitis B cases reported in 1991 was approximately 160,000, giving an incidence of 19 per 100,000 population. This incidence rate varies from 5 per 100,000 in western Europe to 22 per 100,000 in central Europe and 92 per 100,000 in eastern Europe. Because of under-reporting and the fact that two-thirds of infections are asymptomatic, the reported incidence rate considerably underestimates the true incidence of HBV in Europe. For this reason, we may multiply the number of reported cases by a factor of 6 (by 2 for under-reporting and by 3 for the symptomatic/asymptomatic ratio): an estimated 900,000 to 1,000,000 infections of HBV occur in Europe each year. Approximately 90,000 chronic infections will develop from these new cases. The spread of HBV can be controlled by universal infant or adolescent vaccination. A decision-tree-based analytical model was used to assess the clinical and economic impact of these two interventions. The model took into account incidence and prevalence rates of HBV, natural history of infection, compliance and effectiveness of vaccination, and direct and indirect costs. Data were obtained from the literature and from a WHO European survey. The cost-effectiveness ratio amounts to 6443 pounds and 4745 pounds per infection prevented for neonatal and adolescent vaccination, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Cost-Benefit Analysis↗

Cost-effectiveness analysis of vaccination against hepatitis A in travellers.

Hepatitis A virus (HAV) infection is a substantial risk for travellers from low endemic countries to high endemic destinations. Costs and effects of alternative options for prevention were compared using formal decision analysis. General indications for the optimal prevention of hepatitis A were derived from a cost-effectiveness analysis. Various possible strategies for prevention of hepatitis A in travellers were compared to doing nothing: active immunisation using either the existing vaccine (HAVRIX 720) or the new vaccine (HAVRIX 1440); first screening for the presence of HAV antibodies and then vaccinating only susceptibles; and passive immunisation with immunoglobulin. Using a number of assumptions as baseline and for an average duration and frequency of travel from low to high endemic countries, threshold values were obtained for the choice between passive and active immunisation. Passive immunisation remains the most cost-effective prevention strategy for those expected to travel not more frequently than twice over the next 10 years and for short stays (7,000-9,000 pounds per infection prevented). For travellers expected to travel three or more times in 10 years or for trips exceeding a period of 6 months, active immunisation before the first trip is the most cost-effective option (7,500 pounds or less per infection prevented). When travel frequency increases to once a year in the next 10 years, costs per infection prevented decrease to about 3,500 pounds. Screening for the presence of antibodies before vaccination is only justified for older travellers or those leaving from countries with moderate endemicity, i.e., with an average HAV prevalence of at least 30%.

Cost-Benefit Analysis↗

Cost-effectiveness analysis of hepatitis A prevention in travellers.

The advent of new vaccines and the changing epidemiology of hepatitis A call for an update of the economic evaluation of costs and benefits associated with the various alternative preventative strategies. A decision-tree-based model has been developed which enables the calculation of expected costs and expected numbers of hepatitis A virus HAV infections based on different intervention strategies. The model is sufficiently generic to allow for the evaluation of both population-wide strategies and strategies targeted at particular risk groups. An economic analysis focusing on travellers from Europe to high-endemic countries compared a non-intervention strategy to the following three strategies: active immunization with HAV vaccine; screening for HAV antibodies and vaccinating only susceptibles; passive immunization by means of immunoglobulin. The net cost per HAV infection prevented proved very sensitive to a number of important input parameters of the model. These included epidemiological characteristics such as HAV attack rate and prevalence of immunity, behavioural characteristics such as compliance with the vaccination scheme and vaccine characteristics such as rate and duration of protection. Our estimated expected cost per HAV infection prevented among Belgian travellers to high-endemic countries for three weeks per year over ten years amounts to approximately US$4880 for active immunization, US$5621 for screening followed by vaccination of susceptibles and US$29932 for passive immunization. Although these estimates are clearly sensitive to a number of crucial assumptions pertaining to the input parameters of the model, it seems safe to conclude that vaccination is more cost-effective than the currently recommended passive immunization with immunoglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Cost-Benefit Analysis↗

Assessing the economic burden of injuries due to accidents: methodological problems illustrated with some examples from the literature.

This paper provides a survey of methodological problems encountered in an assessment of the economic consequences of accidents in The Netherlands. A sound epidemiological basis for such calculations appears to be lacking due to inadequate data-registration systems. We also discuss some studies of the economic costs of injuries due to accidents for other countries, which have used either a prevalence or an incidence-based approach. It is highlighted that they may be helpful in indicating the relative economic burden posed on society but that they cannot guide priority setting in health care resource allocation. Economic evaluation studies using incidence-based scenario comparisons may be more promising in that respect.

Accidents↗

Supplier-induced demand for physiotherapy in the Netherlands.

Empirical studies of supplier-induced demand in health care have mostly concentrated on the analysis of physician behaviour. In this article, the focus is on the economic determinants of physiotherapist behaviour in The Netherlands. It is shown that relative prices work as strong incentives to alter the mix of services supplied, conform to the model of revenue maximization under a production constraint. However, the time-series analysis also gives some indication that this ability to influence the demand for their services to increase hourly income is not fully exploited. The latter finding is inconsistent with pure income maximization but rather points to a trade-off between loss of revenue and demand manipulation. The fact that the choice of therapy varies with the pressure on provider incomes does not cast some doubt on the appropriateness of the chosen patterns of treatment in terms of effectiveness.

Health Services Needs and Demand↗

The pH dependence and group modification of beta-D-xylosidase from Bacillus pumilus: evidence for sulfhydryl and histidyl groups.

The pH dependence of the kinetic parameters of beta-D-xylosidase (EC. 3.2.1.37) from Bacillus pumilus reveals that an acidic functional group with pK 8.0 is involved in the catalysis. The fast inactivation of the dimeric enzyme by near equivalent amounts of methylmethanethiolsulfonate indicates that one thiol group per monomer is essential for catalysis, consistent with previously reported results. From the reactivity of the thiol groups with respect to 5,5'-dithiobis(2-nitrobenzoic acid), the absence of subunit cooperativity was indicated. The present study also reports on the inactivation of the enzyme by diethylpyrocarbonate, and provides evidence of the importance of a histidine residue. A mechanism of catalysis is presented, in which the thiol group interacts with the substrate via partial proton transfer. The mode of participation of the histidine group is difficult to specify, but may be associated with the maintenance of the active conformation of the enzyme.

Allosteric Site↗

Binding of alkyl beta-D-xylopyranosides, containing branched-chain, cyclic, and substituted aglycon groups, to beta-D-xylosidase from Bacillus pumilus PRL B12.

For a number of alkyl beta-D-xylopyranosides having branched-chain, cyclic, and substituted aglycon groups, and binding to beta-D-xylosidase from B. pumilus PRL B12, the binding constant Ki and (for some of them) the thermodynamic equilibrium parameters delta H0, delta S0, and delta G0 have been determined. Although the aglycon is bound through hydrophobic forces, no simple relationships between the binding parameters and the relative hydrophobicity of the alkyl beta-D-xylopyranosides could be demonstrated. All of the available evidence suggests that the aglycon sub-site has a highly specific structure which forces the atoms of the aglycon group to occupy well-defined positions. The supplementary energy-requirements resulting from the imposed restrictions seem to be the main reason for the irregular way in which the binding parameters depend on the aglycon structure.

Bacillus↗

Binding of n-alkyl beta-D-xylopyranosides and n-alkyl 1-thio-beta-D-xylopyranosides to beta-D-xylosidase from Bacillus pumilus PRL B12.

The binding of D-xylose and of a series of n-alkyl beta-D-xylopyranosides and their 1-thio analogues to beta-D-xylosidase from B. pumilus PRL B12 has been investigated. The binding constants and thermodynamic equilibrium parameters delta H0 and delta S0 have been determined. The enzyme does not distinguish between alpha- and beta-D-xylopyranose. Although the enthalpy of binding of D-xylose is very favourable, the overall free-energy is small, due to a large decrease in entropy. Furthermore, all of the evidence available suggests that the aglycon group is bound by unspecific, hydrophobic forces. However, simple correlations between the binding parameters and the relative hydrophobicity of the compounds could not be found. Unexpectedly, no parallelism between binding of n-alkyl beta-D-xylopyranosides and the corresponding 1-thio derivatives was found.

Bacillus↗

beta-D-xylosidase from Bacillus pumilus PRL B12: hydrolysis of aryl beta-D-xylopyranosides.

The influence of substituents on the binding and hydrolysis of several substituted beta-D-xylopyranosides by beta-D-xylosidase from Bacillus pumilus PRL B12 has been investigated. From a comparison of the inhibition constants of 1-thio-beta-D-xylopyranosides with the apparent Michaelis-Menten constants of the substrates, it followed that the latter constants are good approximations of the true equilibrium constants. The influence of the substituent on the rate and activation parameters is small. The results are in agreement with, but do not prove, a one-step mechanism without the formation of a glycosyl-enzyme intermediate.

Bacillus↗